ArticleClinicoEconomics and outcomes research : CEOR2023

Cost-Effectiveness of Lorlatinib for the Treatment of Adult Patients with Anaplastic Lymphoma Kinase Positive Advanced Non-Small Cell Lung Cancer in Spain.

María Presa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.